A Phase III trial of 2 Years of Androgen Suppression (AS) and Radiation Therapy (RT) with or without Adjuvant Chemotherapy (CT) for High-Risk Prostate Cancer: Final Results of Radiation Therapy Oncology Group (RTOG) Phase III Randomized Trial NRG Oncology RTOG 9902

PURPOSE: Long-term (LT) androgen suppression (AS) with RT is a standard treatment for high-risk, localized prostate cancer (PCa). RTOG 9902 was a randomized trial testing the hypothesis that adjuvant combination chemotherapy (CT) with paclitaxel, estramustine, and oral etoposide (TEE) + LT AS+ RT wo...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Int J Radiat Oncol Biol Phys
Hlavní autoři: Rosenthal, Seth A., Hunt, Daniel, Sartor, A. Oliver, Pienta, Kenneth J., Gomella, Leonard, Grignon, David, Rajan, Raghu, Kerlin, Kevin J., Jones, Christopher U., Dobelbower, Michael, Shipley, William U., Zeitzer, Kenneth, Hamstra, Daniel A., Donavanik, Viroon, Rotman, Marvin, Hartford, Alan C., Michalski, Jeffrey, Seider, Michael, Kim, Harold, Kuban, Deborah A., Moughan, Jennifer, Sandler, Howard
Médium: Artigo
Jazyk:Inglês
Vydáno: 2015
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4719152/
https://ncbi.nlm.nih.gov/pubmed/26209502
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ijrobp.2015.05.024
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky